Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on Arcutis Biotherapeutics (NASDAQ: ARQT) and increased the price target from $38 to $44. This adjustment reflects a positive outlook on the company's performance.